Neurocrine upped to overweight by Piper, sees '568 as still viable08/30/2024 Neurocrine upped to overweight by Piper, sees ‘568 as still viable Source: Seekingalpha
Neurocrine stock dips even as schizophrenia drug meets main goal in study08/29/2024 Neurocrine stock dips even as schizophrenia drug meets main goal in study Source: Seekingalpha
